tiprankstipranks
Trending News
More News >

ASKA Pharmaceutical Achieves Record Sales Amidst Rising R&D Costs

Story Highlights
ASKA Pharmaceutical Achieves Record Sales Amidst Rising R&D Costs

Confident Investing Starts Here:

An announcement from ASKA Pharmaceutical Holdings Co., Ltd. ( (JP:4886) ) is now available.

ASKA Pharmaceutical Holdings Co., Ltd. reported record-high sales in the third quarter of FY2024, driven by continued growth in its pharmaceutical and animal health businesses. Despite increased sales, operating profit remained stable year-over-year due to rising SG&A expenses linked to R&D progress, while the cost of sales ratio improved due to a favorable product mix.

More about ASKA Pharmaceutical Holdings Co., Ltd.

ASKA Pharmaceutical Holdings Co., Ltd. operates in the pharmaceutical industry, focusing on the development and sale of pharmaceuticals and animal health products. The company is known for brand-name drugs such as RELUMINA and RIFXIMA.

YTD Price Performance: -6.29%

Average Trading Volume: 58,094

Technical Sentiment Consensus Rating: Hold

Current Market Cap: Yen55.89B

See more data about 4886 stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App